Carlson J A, Allegra J C, Day T G, Wittliff J L
Am J Obstet Gynecol. 1984 May 15;149(2):149-53. doi: 10.1016/0002-9378(84)90187-x.
Estrogen receptors and progesterone receptors were measured in tumors from patients with previously untreated endometrial carcinoma before and after a 5-day course of tamoxifen citrate. On initial biopsy, 13 of 25 tumors (52%) were progesterone receptor-positive, whereas 21 of 25 tumors (84%) were progesterone receptor-positive after tamoxifen. Grades 1 and 2 tumors were more likely to demonstrate this increased incidence of measurable progesterone receptors. Considering these results, and the work of others who have shown that progesterone receptor-positive metastatic endometrial cancer is more responsive to progestin therapy than are progesterone receptor-negative tumors, we instituted a phase II clinical trial of tamoxifen plus progestin for patients with recurrent endometrial carcinoma. Thus far, however, the 33% total response rate achieved with the combination therapy has not been superior to standard progestin therapy.
在接受枸橼酸他莫昔芬5天疗程治疗前后，对先前未经治疗的子宫内膜癌患者的肿瘤进行雌激素受体和孕激素受体检测。初次活检时，25个肿瘤中有13个（52%）孕激素受体呈阳性，而在接受他莫昔芬治疗后，25个肿瘤中有21个（84%）孕激素受体呈阳性。1级和2级肿瘤更有可能出现这种可测量的孕激素受体发生率增加的情况。考虑到这些结果，以及其他研究表明孕激素受体阳性的转移性子宫内膜癌比孕激素受体阴性肿瘤对孕激素治疗更敏感，我们开展了一项针对复发性子宫内膜癌患者的他莫昔芬加孕激素的II期临床试验。然而，到目前为止，联合治疗所达到的33%的总缓解率并不优于标准孕激素治疗。
